Navigation Links
Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder
Date:2/11/2009

ROCHESTER, Minn., Feb. 11 /PRNewswire-USNewswire/ -- In a study published in The American Journal of Psychiatry, a team of researchers led by Mayo Clinic psychiatrist Mark Frye, M.D., attempted to identify what factors make some people with bipolar depression more likely to experience treatment-emergent mania (TEM).

Bipolar disorder, also known as manic-depressive illness, is a mental illness characterized by severe mood instability that can be serious and disabling. The deep mood swings from high (mania) to low (depression) may last for weeks or months, causing great disturbances in the lives of the person who has the illness, along with family and friends. Drugs known as mood stabilizers have proven effective at controlling the manic phase of the illness, but treating the depressive phase is more problematic. Antidepressants, although effective for some individuals, can trigger a rapid mood switch from depression to mania, a phenomenon called treatment-emergent mania.

"TEM is a serious and sometimes volatile adverse event, and we wanted to better understand who was at risk for developing this problem," says Dr. Frye. People experiencing mania often exhibit poor judgment and impulsivity that can lead them to engage in highly unsafe or personally damaging behaviors, resulting in hospitalization, arrest and/or incarceration.

Dr. Frye's team did a secondary analysis of data obtained in an earlier study led by Robert Post, M.D., and the Bipolar Collaborative Network. In that earlier study, researchers followed 176 study participants diagnosed with bipolar depression to measure the effectiveness of three different antidepressants. The secondary analysis led by Dr. Frye focused on 44 patients who experienced TEM after starting an antidepressant. Dr. Frye's team compared this TEM group to 84 patients who responded favorably to an antidepressant and 44 pa
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... -- BioTrends Research Group, Inc. released Wave 1...the first in a multi-phase syndicated market resea...Biotech,s Stelara, from product launch through the...he report provides quantitative information from 7...n from a subset of 20. The reports assess trial a...
(Date:11/25/2009)... For many of the millions...million living with untreated hearing loss , the ...st Cindy Beyer. ,, Dr. Beyer, senior vice presi...rgest hearing care and hearing aids companies, s...ustration, and social isolation, "which can easily...
(Date:11/25/2009)...PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a s... APFC ) announced today that it received the Envi...at the Annual Statewide Environmental Summit, spon...gy Association (CMTA), the Industrial Environmenta...cil of California (CICC) held in San Diego. This ...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Cruise Ship Virus Vaccine Stems From Tobacco 54758 1Cruise Ship Virus Vaccine Stems From Tobacco 54758 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 1PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 2PetRelocation com and PetMD com Launch Co Branded Pet Travel and Pet Health Resources 54754 3Bankrupt Medicare to be Burdened With 24Billions More for Translation Costs Says ProEnglish 54750 1
...presented at the 90th annual Endocrine Society mee...ected by moderate to severe vaginal ...Mich, June 16 QuatRx Pharmaceuticals today,announ...al Phase 3 clinical,trial of Ophena(TM) (ospemifen...toms of vulvovaginal atrophy, a common condition a...
...lished in the Journal of the American Society of H...giotensin II reversed vascular ... A new study published in the,current Journal of t...hat,the hypertension treatment olmesartan medoxomi...arteries that occurs in patients with hypertension...
Other Medicine Technology:Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 2Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 3Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 2New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 3New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 4New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 5New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 6New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 7New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 8New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering 9
(Date:11/27/2009)..., KELOWNA, BC, Nov. 27 /PRNewswire/ - Uploadabl...eeing prime time in wellness. A combination of adv...ta upload are solving a long term concern over the... to accurately gauge and reward improved participa...logies is one of the first wellness suppliers to i...
(Date:11/27/2009)..., SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCall/...unced that Blair Lambert, CFO/COO, will present at...be held at the May Fair Hotel in London, England, ... ,, To listen to a live broadcast of The Gymbor...lease log on to www.gymboree.com, click on "Our Co...
(Date:11/27/2009)..., KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-F... SHMR ) ( "Shamir" ), a leading provider of innov...ns market, announced today that its board of direc...gregate amount of US$ 10 million (approximately NI...resentative rate of exchange), or approximately US...
(Date:11/27/2009)...g rates to bring unprecedented medical, economic b...27 (HealthDay News) -- The number of people with d... over the next 25 years, a new study predicts. ,... million people with the disease, up from 23.7 mil...eating people with diabetes will triple, the study...
(Date:11/27/2009)... Multi-purpose bilingual colori...ned for use by the business community to educate -... subjects from Safety issues to Dinosuars to ABC,S... Saint Louis, MO (PRWEB) November 27, 2009 --...ronics or toys to keep them busy any hour of the d...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2
...ASPS Twins Study Finds Environmental Factors Trump...Ill., Feb. 3 Your mother,s wrinkles -- or lack th...l age. In fact, a new study claims just the opposi...ge. Results just published on the web-based versio...
...CORTLANDT MANOR, N.Y., Feb. 3 Polymedco is please...to colorectal cancer statistics and screening. It...ns to risks, statistics, and screening options for...ay in the United States. However, with proper scr...
... FORT WORTH, Texas, Feb. 3 Galderma Laboratori...ug Administration (FDA) has approved,Vectical(TM) ...product for the,treatment of mild-to-moderate plaq...ed, scaly patches of skin and,caused by an abnorma...
...Event to Benefit The Larry King Cardiac Foundation...th Annual Red Dress Awards will commemorate Americ...iduals who have made significant contributions to ... Jazz at Lincoln Center,s Allen Room. The View ...
... MIAMI, Feb. 3 Baker & McKenzie, and Banks...009 Summit aimed at informing investors,in the hea...February 12th at,the Harvard Club. , Internati...Center of Miami and Palm Beach, Florida,( http://w...
...CHICAGO, Feb. 3 The Female Health Company (NYSE A...n investor conference call to discuss its operatin... a.m. Eastern Time (EST) on Tuesday, February 10, ...cipate in the conference call by dialing 800-860-2...
Other Medicine News:Health News:Divorce, Antidepressants, or Weight Gain/Loss Can Add Years to Your Face 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 2Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 3Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 4Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 5Health News:Woman's Day Presents the Sixth Annual 'Red Dress Awards' Honoring Women Making Strides in the Fight Against Heart Disease 6Health News:James G. Schwade, M.D. to Deliver Keynote Address to Financial and Investment Industry in New York 2Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
Long Handle Occluder - White
Long Handle Occluder - Black
49 Pinhole short handle
Red Maddox and Red lens
Medicine Products: